Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors and has
high morbidity and mortality rates. Central nervous system (CNS) metastasis is one of the …

Purpose: We report the final analysis of JVDL (NCT02789345), which examined the
combination of the EGFR tyrosine kinase inhibitor (TKI) osimertinib plus the VEGFR2 …

Brain metastases (BM) continue to represent an unmet clinical need in oncology.
Immunotherapy and targeted therapy hold great promise in the treatment of BM. Emerging …

Cancer cells generate protons (H+) that are extruded to the extracellular medium mainly via
the Na+/H+ exchanger 1 (NHE1), which regulates intracellular pH (pHi) and cell …

Administration of bevacizumab to patients with brain metastases (BM) is controversial due to
concerns about the increased risk of intracranial hemorrhage (ICH). This meta-analysis …

Recurrence of lung adenocarcinoma has become one of the most frequent causes of major
cancer incidence and mortality worldwide according to its frequently gained resistance to …

This study evaluates the efficacy and safety of bevacizumab (BEV) in the treatment of non-
small cell lung cancer (NSCLC) patients with brain metastases (BM) by performing meta …

Controversial value of prophylactic cranial irradiation (PCI) in NSCLC in terms of survival
benefit prompted us to explore the possible risk factors for brain metastasis (BM) during the …

Background Ramucirumab plus docetaxel combination therapy (DOC/RAM) for advanced
non-small cell lung cancer (NSCLC) achieves favorable outcomes; however, efficacy and …

Introduction: The 2019 coronavirus disease (COVID-19) pandemic has reshaped oncology
practice, but the impact of anti-angiogenic drugs on the severity of COVID-19 in patients with …